search
Back to results

Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes (DBB48)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
n-3 PUFAs
Placebo
Sponsored by
Laval University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 55 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • age between 18 and 55 years,
  • plasma TG levels above the 50th percentile for age,
  • non-smoker,
  • BMI between 25.0 and 40.0 kg/m2,
  • stable body weight for at least 6 months prior to the study baseline,
  • HbA1c between 6.5 and 8.5%,
  • baseline fasting plasma glucose < 15.0 mmol/L
  • patients with de novo type 2 diabetes not taking oral hypoglycemic agents -- - or patients having received stable doses of metformin for at least 3 months before randomization.

Exclusion Criteria:

  • extreme dyslipidemias such as familial hypercholesterolemia,
  • patients with secondary form of diabetes or acute metabolic diabetic complications,
  • patients having received or being treated with insulin or a thiazolidinedione within the past 6 months,
  • subjects having CVD (CHD, cerebrovascular disease or peripheral arterial disease)
  • subjects taking medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents,
  • significant alcohol intake

Sites / Locations

  • Laval University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

n-3 PUFAs

Corn and soybean oil pill

Arm Description

Outcomes

Primary Outcome Measures

Change in the in vivo kinetics of intestinally derived apoB-48-containing lipoproteins between the two 8-week interventions

Secondary Outcome Measures

Change in the expression of genes that regulate intestinal lipid absorption (NPC1L1, ABCG5/8, FABP, SREBP-1c) and synthesis (DGAT, ACAT2, HMG CoA reductase) as well as synthesis of apoB-48-containing lipoproteins (MTP)between the two 8-week interventions
Change in the plasma surrogates of cholesterol absorption (campesterol, beta-sitosterol) and synthesis (lathosterol) between the two 8-week interventions

Full Information

First Posted
October 6, 2011
Last Updated
February 28, 2013
Sponsor
Laval University
search

1. Study Identification

Unique Protocol Identification Number
NCT01449773
Brief Title
Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes
Acronym
DBB48
Official Title
Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The overaccumulation of apoB-48-containing lipoproteins of intestinal origin seen in patients with type 2 diabetes are now thought to be attributable to elevated intestinal production and reduced clearance. Substantial evidence exists indicating that elevated plasma levels of these lipoproteins are associated with increased cardiovascular disease risk. Therefore, reduction of atherogenic plasma triglyceride-rich lipoproteins (TRL) levels of intestinal origin appears to be crucial to improve CVD risk associated with type 2 diabetes. In this regard, n-3 PUFAs have been shown to exert beneficial effects on diabetic dyslipidemia. However, the investigators understanding of the physiological changes that occur with n-3 PUFA supplementation is suboptimal, thereby limiting the investigators appreciation of its impact on CVD risk associated with type 2 diabetes. The effects of n-3 PUFAs on the intestinal production of TRLs and the expression of genes regulating intestinal lipid absorption and chylomicron synthesis have not yet been examined in humans. The general objective of the proposed research is to investigate the mechanisms by which n-3 PUFAs beneficially modify intestinal lipoprotein metabolism in patients with type 2 diabetes. The investigators hypothesize that n-3 PUFA supplementation in men with type 2 diabetes will: reduce TRL apoB-48 production rate and increase fractional catabolic rate of these lipoproteins, decrease the expression of genes that regulate intestinal lipid absorption and synthesis as well as synthesis of apoB-48-containing lipoproteins, decrease both plasma surrogates of cholesterol absorption and cholesterol synthesis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
n-3 PUFAs
Arm Type
Experimental
Arm Title
Corn and soybean oil pill
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
n-3 PUFAs
Intervention Description
5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
5 capsules/day containing corn and soybean oil
Primary Outcome Measure Information:
Title
Change in the in vivo kinetics of intestinally derived apoB-48-containing lipoproteins between the two 8-week interventions
Time Frame
At the end of the two 8-week interventions
Secondary Outcome Measure Information:
Title
Change in the expression of genes that regulate intestinal lipid absorption (NPC1L1, ABCG5/8, FABP, SREBP-1c) and synthesis (DGAT, ACAT2, HMG CoA reductase) as well as synthesis of apoB-48-containing lipoproteins (MTP)between the two 8-week interventions
Time Frame
At the end of the two 8-week interventions
Title
Change in the plasma surrogates of cholesterol absorption (campesterol, beta-sitosterol) and synthesis (lathosterol) between the two 8-week interventions
Time Frame
At the end of the two 8-week interventions

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age between 18 and 55 years, plasma TG levels above the 50th percentile for age, non-smoker, BMI between 25.0 and 40.0 kg/m2, stable body weight for at least 6 months prior to the study baseline, HbA1c between 6.5 and 8.5%, baseline fasting plasma glucose < 15.0 mmol/L patients with de novo type 2 diabetes not taking oral hypoglycemic agents -- - or patients having received stable doses of metformin for at least 3 months before randomization. Exclusion Criteria: extreme dyslipidemias such as familial hypercholesterolemia, patients with secondary form of diabetes or acute metabolic diabetic complications, patients having received or being treated with insulin or a thiazolidinedione within the past 6 months, subjects having CVD (CHD, cerebrovascular disease or peripheral arterial disease) subjects taking medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Couture, MD, PhD, FRCP
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laval University
City
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
23855973
Citation
Labonte ME, Couture P, Tremblay AJ, Hogue JC, Lemelin V, Lamarche B. Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. Nutr J. 2013 Jul 15;12:98. doi: 10.1186/1475-2891-12-98.
Results Reference
derived

Learn more about this trial

Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes

We'll reach out to this number within 24 hrs